Literature DB >> 12487123

Aspartoacylase is restricted primarily to myelin synthesizing cells in the CNS: therapeutic implications for Canavan disease.

Batool F Kirmani, David M Jacobowitz, Abraham T Kallarakal, M A A Namboodiri.   

Abstract

Canavan disease is a devastating neurodegenerative childhood disease caused by mutations in aspartoacylase, an enzyme that deacetylates N-acetylaspartate to generate free acetate in the brain. Localization of aspartoacylase in different cell types in the rat brain was examined in an attempt to understand the pathogenesis of Canavan disease. In situ hybridization histochemistry with a riboprobe based on murine aspartoacylase cDNA was used in this study. The hybridization signal was detectable primarily in the myelin-synthesizing cells, namely oligodendroglia. These findings provide strong additional support for insufficient myelin synthesis as the pathogenic basis of Canavan disease and make a compelling case for acetate supplementation as a simple and noninvasive therapy for this fatal disease with no treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12487123     DOI: 10.1016/s0169-328x(02)00490-4

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  14 in total

1.  Nuclear-cytoplasmic localization of acetyl coenzyme a synthetase-1 in the rat brain.

Authors:  Prasanth S Ariyannur; John R Moffett; Chikkathur N Madhavarao; Peethambaran Arun; Nisha Vishnu; David M Jacobowitz; William C Hallows; John M Denu; Aryan M A Namboodiri
Journal:  J Comp Neurol       Date:  2010-08-01       Impact factor: 3.215

Review 2.  N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.

Authors:  John R Moffett; Brian Ross; Peethambaran Arun; Chikkathur N Madhavarao; Aryan M A Namboodiri
Journal:  Prog Neurobiol       Date:  2007-01-05       Impact factor: 11.685

3.  Restricted diffusion in Canavan disease.

Authors:  S G Srikanth; H S Chandrashekar; K Nagarajan; P N Jayakumar
Journal:  Childs Nerv Syst       Date:  2007-01-12       Impact factor: 1.475

4.  In Vivo Neurochemical Characterization of Developing Guinea Pigs and the Effect of Chronic Fetal Hypoxia.

Authors:  Wen-Tung Wang; Phil Lee; Yafeng Dong; Hung-Wen Yeh; Jieun Kim; Carl P Weiner; William M Brooks; In-Young Choi
Journal:  Neurochem Res       Date:  2016-05-27       Impact factor: 3.996

5.  Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease.

Authors:  Chikkathur N Madhavarao; Peethambaran Arun; John R Moffett; Sylvia Szucs; Sankar Surendran; Reuben Matalon; James Garbern; Diana Hristova; Anne Johnson; Wei Jiang; M A Aryan Namboodiri
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-22       Impact factor: 11.205

6.  Long-term follow-up after gene therapy for canavan disease.

Authors:  Paola Leone; David Shera; Scott W J McPhee; Jeremy S Francis; Edwin H Kolodny; Larissa T Bilaniuk; Dah-Jyuu Wang; Mitra Assadi; Olga Goldfarb; H Warren Goldman; Andrew Freese; Deborah Young; Matthew J During; R Jude Samulski; Christopher G Janson
Journal:  Sci Transl Med       Date:  2012-12-19       Impact factor: 17.956

7.  Intracerebroventricular administration of N-acetylaspartic acid impairs antioxidant defenses and promotes protein oxidation in cerebral cortex of rats.

Authors:  Carolina Didonet Pederzolli; Francieli Juliana Rockenbach; Fernanda Rech Zanin; Nicoli Taiana Henn; Eline Coan Romagna; Angela M Sgaravatti; Angela T S Wyse; Clóvis M D Wannmacher; Moacir Wajner; Angela de Mattos Dutra; Carlos S Dutra-Filho
Journal:  Metab Brain Dis       Date:  2009-03-18       Impact factor: 3.584

Review 8.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016

9.  Mutational analysis of aspartoacylase: implications for Canavan disease.

Authors:  Jeremy R Hershfield; Nagarajan Pattabiraman; Chikkathur N Madhavarao; M A Aryan Namboodiri
Journal:  Brain Res       Date:  2007-03-03       Impact factor: 3.252

10.  A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice.

Authors:  Seemin Seher Ahmed; Huapeng Li; Chunyan Cao; Elif M Sikoglu; Andrew R Denninger; Qin Su; Samuel Eaton; Ana A Liso Navarro; Jun Xie; Sylvia Szucs; Hongwei Zhang; Constance Moore; Daniel A Kirschner; Thomas N Seyfried; Terence R Flotte; Reuben Matalon; Guangping Gao
Journal:  Mol Ther       Date:  2013-07-02       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.